Contents
Side Effect Overview
GLP-1 medications are generally well tolerated but do produce a predictable pattern of side effects — almost all gastrointestinal in nature. The key facts to know upfront:
- Side effects are most common and most intense during dose escalation, not at steady maintenance dose
- The dose escalation schedule is specifically designed to minimize side effects by allowing gradual adaptation — never skip steps
- Most people find side effects are mild to moderate and temporary, improving significantly by weeks 8–12
- About 5–10% of patients discontinue due to intolerable side effects
- Tirzepatide (Mounjaro/Zepbound) causes significantly less nausea than semaglutide (Ozempic/Wegovy)
| Side Effect | Wegovy (sema 2.4mg) | Zepbound (tirz 15mg) | Typical Duration |
|---|---|---|---|
| Nausea | 44% | 18% | Weeks 1–8, then improves |
| Diarrhea | 30% | 17% | Variable, usually weeks 2–6 |
| Vomiting | 24% | 9% | Weeks 1–8 |
| Constipation | 24% | 11% | Ongoing, manageable |
| Abdominal pain | 20% | 9% | Variable |
| Headache | 14% | 8% | Weeks 1–4 |
| Fatigue | 11% | 8% | Weeks 1–4 |
Nausea
Nausea is the most common side effect of GLP-1 medications and the primary reason patients discontinue treatment. It results from two mechanisms: GLP-1 receptor activation in the brainstem's nausea centers, and delayed gastric emptying causing food to sit longer in the stomach.
🤢 Nausea
Very Common — 18–44%Usually peaks in the first 2–4 weeks after each dose increase and improves significantly by weeks 6–10. The nausea window is typically 4–8 hours after injection.
- Inject at bedtime — sleep through the 4–8 hour peak nausea window
- Eat smaller portions — stop eating the moment you feel satisfied, don't push through fullness
- Eat slowly and chew thoroughly — rapid eating overwhelms a slowed digestive system
- Avoid trigger foods on injection day: fatty meals, very sweet foods, spicy food, alcohol
- Stay upright for at least 1 hour after eating — lying down worsens nausea
- Ginger — ginger tea, ginger chews, or ginger capsules are evidence-backed for GI nausea
- Small cold meals are better tolerated than hot, aromatic meals when nausea is active
- Stay hydrated — sip water or electrolyte drinks throughout the day
- Ask your doctor about ondansetron (Zofran) or other anti-nausea medications if nausea is severe and persistent
💡 The most effective single intervention for GLP-1 nausea is switching injection time to before bed. Most patients who do this report dramatically reduced nausea awareness simply by being asleep during the peak plasma concentration window.
Vomiting
🤮 Vomiting
Common — 9–24%Vomiting is more common with semaglutide than tirzepatide. It typically occurs in conjunction with nausea during early treatment or dose increases. Persistent vomiting can lead to dehydration.
- Do not eat large meals — eat half your normal portion and wait 20 minutes before deciding if you want more
- Avoid eating within 2 hours of bedtime — lying down with a full stomach increases vomiting risk
- Sip fluids constantly rather than drinking large amounts at once
- If vomiting more than 3 times in one day, contact your provider — dehydration risk is significant
- Electrolyte drinks (Pedialyte, Liquid IV) prevent dehydration better than water alone during active vomiting
- A dose pause or reduction may be appropriate — discuss with your prescriber if vomiting persists beyond 1 week at any dose
⚠️ Persistent vomiting can cause dehydration which may in turn cause acute kidney injury. If you cannot keep fluids down for more than 24 hours, seek medical care. IV fluids may be needed.
Diarrhea
🚽 Diarrhea
Common — 17–30%GLP-1 diarrhea results from accelerated intestinal transit. It is usually loose stools rather than watery diarrhea and often resolves within a few weeks.
- Stay hydrated with electrolyte-containing fluids — diarrhea causes significant fluid and electrolyte losses
- Avoid high-fat and high-sugar foods which worsen GI transit speed
- Soluble fiber (oats, psyllium, bananas) can help normalize stool consistency
- Probiotics — some evidence supports their use for GLP-1 related GI symptoms
- Over-the-counter loperamide (Imodium) can provide short-term relief — ask your doctor if appropriate
- If diarrhea persists beyond 2 weeks or is severe, notify your prescriber
Constipation
😣 Constipation
Common — 11–24%Constipation is caused by significantly delayed gastric emptying — food moves more slowly through the entire GI tract. It is often more persistent than other GI side effects and may require ongoing management.
- Hydration first — drink at least 8–10 glasses of water daily
- Increase fiber gradually — target 25–35g/day from vegetables, fruits, legumes, and whole grains
- Walk daily — even 15–20 minutes of walking stimulates bowel motility
- Magnesium citrate (200–400mg at bedtime) is safe, effective, and commonly recommended for GLP-1 constipation
- Polyethylene glycol (MiraLax) is a gentle osmotic laxative appropriate for regular use if needed
- Avoid stimulant laxatives as a first-line approach — save these for acute episodes
- If no bowel movement for 3+ days with discomfort, contact your provider
Other Common Side Effects
🤕 Headache
Common — 8–14%Headaches in the first few weeks are usually caused by reduced caloric intake, dehydration, or caffeine reduction rather than a direct drug effect. They typically resolve within 2–4 weeks.
- Ensure adequate hydration — aim for pale yellow urine throughout the day
- Do not reduce caffeine intake abruptly when starting GLP-1 therapy
- Maintain consistent meal timing even if portions are smaller
- Over-the-counter pain relievers are appropriate for symptom relief
😴 Fatigue
Common — 8–11%Fatigue in early treatment typically results from reduced caloric intake. It usually resolves within 3–4 weeks as metabolism adapts.
- Ensure you are eating enough — extremely low caloric intake is not appropriate on GLP-1 therapy
- Prioritize protein intake to maintain energy and lean mass
- Light exercise often improves energy levels despite initial fatigue
- Persistent fatigue beyond 4 weeks warrants a blood test — thyroid and iron levels should be checked
💉 Injection Site Reactions
Uncommon — 3–6%Redness, itching, bruising, or small lumps at the injection site. Usually mild and temporary. Lipohypertrophy from repeated injections in the same spot can reduce drug absorption.
- Rotate injection sites every week — abdomen, thigh, upper arm in a consistent rotation
- Allow the pen to reach room temperature before injecting (30 minutes out of refrigerator)
- Inject into subcutaneous fat, not muscle — pinch the skin if you are lean
- Do not inject into areas with existing bruising, scars, or hardened tissue
💓 Increased Heart Rate
Common — seen in trialsGLP-1 medications increase resting heart rate by an average of 2–4 beats per minute. This is generally clinically insignificant but can be noticeable in people who monitor their heart rate closely.
- Usually not clinically significant or requiring treatment
- If you experience palpitations, dizziness, or heart rate consistently above 100 bpm, notify your doctor
- People with pre-existing cardiac arrhythmias should discuss this effect with their cardiologist
Ozempic Face
"Ozempic face" is a colloquial term describing facial volume loss, sagging, and a gaunt appearance that some patients experience during rapid weight loss on GLP-1 therapy. It is not a direct drug side effect — it is a consequence of rapid weight loss from any cause.
Why It Happens
The face contains significant subcutaneous fat deposits that contribute to a youthful, full appearance. When you lose weight rapidly, facial fat is lost alongside body fat — and the overlying skin, which has less elasticity with age, does not contract back fully, leading to a hollowed or aged look.
Who Is Most Affected
- People over age 40 (skin elasticity decreases with age)
- People losing weight very rapidly (more than 1–2 lbs/week)
- People losing very large amounts of weight (20%+ of body weight)
Prevention and Management
- Slower weight loss — losing 0.5–1 lb/week gives skin more time to adapt
- Adequate protein intake — preserves skin structure proteins (collagen, elastin)
- Sun protection — UV damage accelerates skin sagging during weight loss
- Hydration — dehydrated skin sags more visibly
- Cosmetic options: dermal fillers, collagen stimulators, or radiofrequency treatments — consult a dermatologist or plastic surgeon
💡 Ozempic face is not medically dangerous. For most people, the health benefits of significant weight loss far outweigh cosmetic concerns.
Serious Side Effects — Know the Warning Signs
🚨 Seek emergency care immediately if you experience: severe and persistent abdominal pain (possible pancreatitis), sudden vision changes, rapid heart rate with dizziness or fainting, severe allergic reaction (hives, swelling, difficulty breathing), or signs of thyroid tumor (neck lump, hoarseness, difficulty swallowing).
Pancreatitis
Acute pancreatitis is a rare but serious GLP-1 complication. Symptoms include sudden, severe abdominal pain — often radiating to the back — with nausea and vomiting that is constant and does not improve with position changes. Stop GLP-1 therapy immediately if pancreatitis is suspected. Risk is higher in people with prior pancreatitis, gallstones, or heavy alcohol use.
Gallbladder Disease
GLP-1 medications increase the risk of gallstones and cholecystitis, likely because rapid weight loss promotes gallstone formation and GLP-1 slows gallbladder emptying. Symptoms include right upper abdominal pain (especially after fatty meals), nausea, and fever.
Diabetic Retinopathy Worsening
In patients with pre-existing diabetic retinopathy, rapid improvement in blood sugar can paradoxically worsen retinopathy in some cases. All diabetic patients starting GLP-1 therapy should have a baseline eye exam and follow-up as recommended by their ophthalmologist.
Kidney Injury
Acute kidney injury has been reported, generally as a consequence of severe dehydration from vomiting and diarrhea. Staying well hydrated and seeking care promptly for persistent vomiting prevents this complication.
Thyroid C-Cell Tumors (Boxed Warning)
All GLP-1 medications carry an FDA boxed warning for potential medullary thyroid carcinoma (MTC) risk, based on rodent studies. This risk has not been confirmed in humans, but the contraindication is firm: do not use GLP-1 medications if you have a personal or family history of MTC or MEN 2.
Semaglutide vs Tirzepatide — Side Effect Comparison
If you are experiencing significant side effects on semaglutide (Ozempic/Wegovy), switching to tirzepatide (Mounjaro/Zepbound) may significantly improve tolerability:
| Side Effect | Semaglutide | Tirzepatide | Better Tolerated |
|---|---|---|---|
| Nausea | ~44% (Wegovy) | ~18% (Zepbound) | Tirzepatide |
| Vomiting | ~24% | ~9% | Tirzepatide |
| Diarrhea | ~30% | ~17% | Tirzepatide |
| Constipation | ~24% | ~11% | Tirzepatide |
| Discontinuation (GI) | Higher | Lower | Tirzepatide |
| Thyroid warning | Yes (boxed) | Yes (boxed) | Equal |
| Pancreatitis risk | Low (rare) | Low (rare) | Equal |
When to Stop the Medication
Stop your GLP-1 medication and contact your doctor immediately if you experience:
- Severe, persistent abdominal pain (possible pancreatitis)
- Inability to keep fluids down for more than 24 hours
- Signs of serious allergic reaction (swelling, hives, breathing difficulty)
- Sudden vision changes
- A neck lump, difficulty swallowing, or unexplained hoarseness
- Signs of severe dehydration (very dark urine, extreme dizziness, no urination)
Consider discussing a dose reduction (not stopping) with your doctor if you experience:
- Nausea or vomiting that has not improved after 4 weeks at a new dose
- Significant weight loss that has you below a healthy BMI
- Inability to eat enough to maintain adequate nutrition